Mode
Text Size
Log in / Sign up

Percutaneous Coronary Intervention

Part of Coronary Artery Disease

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Percutaneous Coronary Intervention

15 trials tracked for Percutaneous Coronary Intervention: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 153 citations.

15Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 4 Phase 2 1 Other / NA 7
  1. Phase 4 Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI Completed · 153 cited
  2. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 77 cited
  3. Phase 3 Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) Completed · 24 cited
  4. Phase 4 Adenosine Contrast CorrELations in Evaluating RevAscularizaTION Completed
  5. Phase 4 Chewed Versus Integral Pill of Ticagrelor Completed
  6. Phase 3 A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Completed
Show 9 more trials
  1. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  2. Phase 2 Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56 Completed
  3. N/A Efficacy of Long Term Plavix Therapy Post Angioplasty Completed
  4. N/A Improving Cardiac Rehabilitation Outcomes Through Mobile Case Management (iCARE) Completed
  5. N/A Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure Completed
  6. N/A Cardiac Rehabilitation Peer Mentorship Completed
  7. N/A RAVE: Radial Artery Vascular Complication and Resource Utilization Completed
  8. N/A A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk Completed
  9. N/A GRX With ReMOTE: First in Human in India Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Percutaneous Coronary Intervention: what the trials found

Clinical trials have evaluated various pharmacological agents and interventions in the context of Percutaneous Coronary Intervention. Cangrelor was shown to significantly impact platelet reactivity as measured by VerifyNow PRU (63; 214, p<0.001) 2. Other established investigations included studies on Iopamidol 3, Ticagrelor [4, 7], and the P2Y12 inhibitor cangrelor 8.

Regarding anticoagulation and bleeding risks, rivaroxaban 2.5 mg was evaluated for clinically significant bleeding (15.7; 16.6; 24.0, p<0.001), while TIMI major and minor bleeding rates did not show statistically significant differences across groups (p=0.234 and p=0.144, respectively) 5. Dabigatran Etexilate 110mg was also studied, showing no significant difference in the time to death of undetermined cause or non-cardiovascular causes 6.

Recent results — preliminary, needs further review

  • Center-Based Cardiac Rehab is currently being evaluated as a new intervention 1.
  • Clopidogrel (not yet corroborated) 9
  • Wellframe (not yet corroborated) 10
  • RadAR EasyCLik plus ®-STF hemostatic pad (not yet corroborated) 11
  • Axiostat® (not yet corroborated) 12

For the clinician treating this condition

  • Cangrelor significantly affects platelet reactivity in patients undergoing intervention 2.
  • Rivaroxaban 2.5 mg is associated with clinically significant bleeding, though TIMI major and minor bleeding rates were not statistically different across cohorts 5.
  • Dabigatran Etexilate 110mg did not show significant differences in time to death of undetermined cause or non-cardiovascular causes 6.

AI synthesis of 10 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Coronary Artery Disease

Related studies from across the Coronary Artery Disease family.

Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
Cardiology Sys. Review
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Staged PCI reduces severe kidney injury risk after TAVR in aortic stenosis and CAD
Cardiology Meta-analysis
Staged PCI reduces severe kidney injury risk after TAVR in aortic stenosis and CAD Staged heart procedures may lower risk of severe kidney injury
This meta-analysis of 7,119 patients with aortic stenosis and coronary artery disease undergoing TAVR found that staged PCI did not signific…
A new look at heart surgery data suggests that spacing out certain procedures could protect kidneys from severe damage.
SK-121 digital health program improves disease knowledge and medication adherence after PCI
Cardiology RCT
SK-121 digital health program improves disease knowledge and medication adherence after PCI Digital health program improves knowledge and blood pressure for heart patients
This single-centre RCT of 200 patients found that the SK-121 multimodal digital health program did not significantly reduce the SMART2 risk …
A digital health program helped heart patients improve their medical knowledge, medication habits, and blood pressure after a procedure.
Extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk
Cardiology RCT
Extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk Extended dual antiplatelet therapy lowers risks for heart disease patients
This randomized trial of 8250 patients with multivessel coronary artery disease found that extending dual antiplatelet therapy (DAPT) for an…
Patients with coronary artery disease may have lower risks of stroke and heart attack when taking two blood thinners for an extra year.
Comparative Efficacy and Safety of Drug Coated Balloons Versus Drug Eluting Stents
Cardiology Meta-analysis
Comparative Efficacy and Safety of Drug Coated Balloons Versus Drug Eluting Stents Drug-coated balloons show lower bleeding rates than stents
A meta-analysis reveals that drug-coated balloons offer comparable clinical outcomes to drug-eluting stents while significantly reducing maj…
A large review of heart procedures shows drug-coated balloons offer a viable alternative to stents with fewer major bleeding risks for patie…
Postoperative educational interventions significantly reduce anxiety and depression in patients following coronary artery bypass grafting
Cardiology Meta-analysis
Postoperative educational interventions significantly reduce anxiety and depression in patients following coronary artery bypass grafting Educational programs help patients after heart bypass surgery
This meta-analysis of 1,669 patients found that postoperative educational interventions significantly reduced anxiety (SMD = -0.48) and depr…
New research shows that educational programs can lower anxiety and depression for patients recovering from coronary artery bypass grafting.
21% hypertension prevalence in transgender adults: meta-analysis of cardiovascular morbidities
Cardiology Meta-analysis
21% hypertension prevalence in transgender adults: meta-analysis of cardiovascular morbidities Transgender adults face high rates of heart disease
This meta-analysis of observational studies reports pooled prevalence of major cardiovascular morbidities among transgender adults aged ≥18 …
One in five transgender adults has high blood pressure, and many have heart disease, a new analysis finds.
Intravascular lithotripsy reduces mortality risk and MACE in calcified coronary lesions compared to rotational atherectomy
Cardiology Meta-analysis
Intravascular lithotripsy reduces mortality risk and MACE in calcified coronary lesions compared to rotational atherectomy Intravascular lithotripsy shows better safety for calcified heart lesions
This meta-analysis of 1247 patients with calcified coronary lesions found that intravascular lithotripsy (IVL) significantly reduced mortali…
A new analysis suggests that using sound waves to break up hard calcium in arteries may lower risks like stroke and heart attack.
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions
Cardiology Sys. Review
Patients with cardiovascular diseases show measurable prevalence of active cancer across multiple conditions Heart disease patients show measurable risk of developing various cancers
This systematic review and meta-analysis analyzed 4,759,695 patients to determine the prevalence of active cancer in individuals with variou…
New data shows that people with heart conditions like stroke or heart failure have a measurable rate of active cancer cases.
Genetic Polymorphisms of SIRT1 Gene and Susceptibility to Coronary Artery Disease
Cardiology Meta-analysis
Genetic Polymorphisms of SIRT1 Gene and Susceptibility to Coronary Artery Disease Specific SIRT1 Gene Variations Linked to Coronary Artery Disease Risk
Meta-analysis identifies specific SIRT1 gene polymorphisms associated with increased coronary artery disease risk under distinct genetic mod…
New research identifies specific SIRT1 gene variations that may increase the risk of developing coronary artery disease.
Health literacy is moderately associated with improved self-care behaviors in patients with multiple chronic diseases
Primary Care & Family Medicine Meta-analysis
Health literacy is moderately associated with improved self-care behaviors in patients with multiple chronic diseases Better health literacy helps people manage chronic diseases more effectively
This meta-analysis of 138 studies found a moderate positive association (r = 0.29, 95% CI: 0.26-0.31) between health literacy and self-care …
Understanding medical information and using digital tools can help people with chronic conditions like diabetes or heart failure manage thei…
In-hospital mortality rates for coronary artery disease patients following PCI remain within international benchmarks
Cardiology Meta-analysis
In-hospital mortality rates for coronary artery disease patients following PCI remain within international benchmarks PCI mortality rates in Asia-Pacific region within international benchmarks
This meta-analysis of 27 studies across 16 registries in the Asia-Pacific region reports in-hospital mortality rates between 0.26% and 2.80%…
A large meta-analysis finds in-hospital death rates after PCI in Asia-Pacific range from 0.26% to 2.80%, with most around 0.9-1.6%.

Questions about Percutaneous Coronary Intervention

Can an AI model help doctors decide on my treatment plan for Percutaneous Coronary Intervention?

AI models are not yet proven to help doctors decide on PCI treatment plans; current research focuses on imaging and risk scores, not AI decision support.

Full answer →
Does a higher dose of heparin during elective PCI reduce bleeding complications?

Current evidence does not show that a higher heparin dose reduces bleeding; lower doses may be safer, but definitive results from the HD-PCI trial are pending.

Full answer →
Will stopping aspirin early after my Percutaneous Coronary Intervention cause a heart attack?

Stopping aspirin early after PCI may increase heart attack risk if no other antiplatelet is used, but switching to a P2Y12 inhibitor alone within 3 months does not significantly raise MI risk and reduces bleeding.

Full answer →
Can using intravascular imaging reduce my risk of major adverse events after PCI?

Yes, using intravascular imaging (IVUS or OCT) to guide PCI significantly reduces the risk of major adverse cardiovascular events compared to angiography alone.

Full answer →
Does having metabolic syndrome increase my risk of restenosis after Percutaneous Coronary Intervention?

Current evidence does not show a clear link between metabolic syndrome and higher restenosis risk after PCI, though related factors like insulin resistance may play a role.

Full answer →
See all 5 questions about Percutaneous Coronary Intervention →